Compare ELTX & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | OSUR |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 214.1M |
| IPO Year | 2014 | 2000 |
| Metric | ELTX | OSUR |
|---|---|---|
| Price | $10.69 | $3.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.00 | $3.00 |
| AVG Volume (30 Days) | 134.1K | ★ 527.1K |
| Earning Date | 03-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,301,000.00 | ★ $167,064,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $7.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.60 | $2.08 |
| 52 Week High | $14.93 | $3.76 |
| Indicator | ELTX | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 50.33 |
| Support Level | $9.84 | $2.72 |
| Resistance Level | $11.12 | $2.99 |
| Average True Range (ATR) | 0.99 | 0.17 |
| MACD | -0.26 | -0.02 |
| Stochastic Oscillator | 29.20 | 31.34 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.